Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin

Tumor Biology

Volumn 31, Issue 3, 2010, Pages 225-232

  Wang, Li ^a   Yin, Fang ^a   Du, Yulei ^a   Chen, Bei ^a   Liang, Shuhui ^a   Zhang, Yongguo ^a   Du, Wenqi ^a   Wu, Kaichun ^a   Ding, Jie ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Drug resistance; Gastric cancer; Mitotic arrest deficient 2; Mitotic spindle checkpoint; SiRNA; Survivin

Indexed keywords

CISPLATIN; DOXORUBICIN; PROTEIN MAD2; SMALL INTERFERING RNA; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; CALCIUM BINDING PROTEIN; CELL CYCLE PROTEIN; GLYCOPROTEIN P; MAD2L1 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; RAF PROTEIN; REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; EXPRESSION VECTOR; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MITOTIC ARREST DEFICIENT 2 GENE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; STOMACH CANCER; STOMACH CARCINOGENESIS; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; METABOLISM; PHOSPHORYLATION; STOMACH TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIUM-BINDING PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-RAF; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; STOMACH NEOPLASMS;

EID: 77953237987     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0036-6     Document Type: Article

References (39)

1. Fang G, Yu H, Kirschne MW. Control of mitotic transitions by the anaphase-promoting complex phil. Trans R Soc Lond. 1999; B354:1583-90.
2. Hisaoka M, Matsuyama A, Hashimoto H. Aberrant MAD2 expression in soft-tissue sarcoma. Pathol Int. 2008;58:329-33.
3. Dobles M, Liberal V, Scott ML, Benezra R, Sorger PK. Chromosome missegregation and apoptosis in mice lacking the mitotic checkpoint protein Mad2. Cell. 2000;101(6):635-45.
4. Michel LS, Liberal V, Chatterjee A, Kirchwegger R, Pasche B, Gerald W, et al. MAD2 haploin sufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature. 2001;409:355-9.
5. Pennisi E. Cell division gatekeepers identified. Science. 1998;279:477-8.
6. Hernando E, Orlow I, Liberal V, Nohales G, Benezra R, Cordon- Cardo C. Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer. Int J Cancer. 2001;95(4):223-7.
7. Gemma A, Hosoya Y, Seike M, Uematsu K, Kurimoto F, Hibino S, et al. Genomic structure of the human MAD2 gene and mutation analysis in human lung and breast cancers. Lung Cancer. 2001;32(3):289-95.
8. Imai Y, Shiratori Y, Kato N, Inoue T, Omata MJ. Mutational inactivation of mitotic checkpoint genes, hsMAD2 and hBUB1, is rare in sporadic digestive tract cancers. Cancer Res. 1999;90 (8):837-40.
9. Percy MJ, Myrie KA, Neeley CK, Azim JN, Ethier SP, Petty EM. Expression and mutational analyses of the human MAD2L1 gene in breast cancer cells. Genes, Chromosomes Cancer. 2000;29(4):356-62.
10. Li Y, Benezra R. Identification of a human mitotic checkpoint gene: hsMAD2. Science. 1996;274:246-8.
11. Takahashi T, Haruki N, Nomoto S, Masuda A, Saji S, Osada H, et al. Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes,hsMAD2 and p55CDC, in human lung cancers. Oncogene. 1999;18:4295-300.
12. Wang X, Jin D-Y, Wong YC, Cheung ALM, Chun ACS, Lo AKF. Correlation of defective mitotic checkpoint with aberrantly reduced expression of MAD2 protein in nasopharyngeal carcinoma cells. Carcinogenesis. 2000;21:2293-7.
13. Hisaoka M, Matsuyama A, Hashimoto H. Aberrant MAD2 expression in soft-tissue sarcoma. Pathol Int. 2008;58(6):329-33.
14. Ruddy DA, Gorbatcheva B, Yarbrough G, Schlegel R, Monahan JE. No somatic mutations detected in the Mad2 gene in 658 human tumors. Mutat Res. 2008;641(1-2):61-3.
15. Wang X, Jin D-Y, Ng RWM, Feng H, Wong YC, Cheung ALM, et al. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res. 2002;62:1662-8.
16. Zhao YQ, You H, Liu F, An HZ, Shi YQ, Yu Q et al (2002) Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. Cancer Lett. 185211-8.
17. Yin F, Hu WH, Qiao TD, Fan DM. Multidrug resistant effect of alternative splicing form of MAD2 gene-MAD2beta on human gastric cancer cell. Chin J Oncol. 2004;26:201-4.
18. Yin F, DuY, HuW, QiaoT, Ding J,WuK, et al.Mad2β, an alternative variant of Mad2 reduce mitotic arrest and apoptosis of gastric cancer cells induced by adriamycin. Life Sci. 2006;78:1277-86.
19. Pan Y, Bi F, Liu N, Xue Y, Yao X, Zheng Y, et al. Expression of seven main Rho family members in gastric carcinoma. Biochem Biophys Res Commun. 2004;315(3):686-91.
20. Smits VA, Klompmarker R, Arnaudm L, Rijksen G, Nigg EA, Medema RH. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat. Cell Biol. 2000;2:672-6.
21. Huang T-S, Duyster J, Wang JYJ. Biological response to phorbolester determined by alternative G1 pathway. Proc Natl Acad Sci USA. 1995;92:4793-7.
22. Huang T-S, Shu C-H, Yang WK, Whang-Peng J. Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331 induced apoptosis. Cancer Res. 1997;57:2974-8.
23. Huang T-S, Yang WK, Whang-Peng J. GL331-induced disruption of cyclin B1/CDC2 complex and inhibition of CDC2 kinase activity. Apoptosis. 1996;1:213-7.
24. Sudo T, Nitta M, Saya H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res. 2004;64(7):2502-8.
25. Schwartz GK. Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J Clin Oncol. 2005;20:4499-508.
26. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(4):928-42.
27. Garber PM, Rine J.Overlapping roles of the spindle assembly andDNA damage checkpoints in the cell-cycle response to altered chromosomes in Saccharomyces cerevisiae. Genetics. 2002;161:521-34.
28. Mikhailov A, Cole RW, Rieder CL. DNA damage during mitosis in human cells delays the metaphase/anaphase transition via the spindle-assembly checkpoint. Curr Biol. 2002;12:1797-806.
29. Tulub AA, Stefanov VE. Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanism of antitumor activity of platinum complexes. Int J Biol Macromol. 2001;28:191-8.
30. Chow JP, Siu WY, Fung TK, Chan WM, Lau A, Arooz T, et al. DNA damage during the spindle-assembly checkpoint degrades CDC25A, inhibits cyclin-CDC2 complexes, and reverses cells to interphase. Mol Biol Cell. 2003;14(10):3989- 4002.
31. Musacchio, Hardwick KG (2002) The spindle checkpoint: structural insights into dynamic signaling. Nat. Rev. Mol. Cell. Biol. 3731-41.
32. Cleveland DW, Mao Y, Sullivan KF (2003) Centromeres and kinetochores from epigenetics to mitotic checkpoint signaling. Cell 112407-21.
33. Glotzer M. Mitosis: don't get mad, get even. Curr Biol. 1996;6:1592-4.
34. Wang X, Jin D-Y, Wong HL, Feng H, Wong Y-C, Tsao SW. MAD2-induced sensitisation to vincristine is associated with mitotic arrest and Raf/Bcl-2 phosphorylation in nasopharyngeal carcinoma cells. Oncogene. 2003;22:109-16.
35. Fung MKL, Han H-Y, Leung SCL, Cheung HW, Cheung ALM, Wong Y-C, et al. MAD2 interacts with DNA repair proteins and negatively regulates DNA damage repair. J Mol Biol. 2008;381 (1):24-34.
36. Zhang P, Cong B, Yuan H, Chen L, Lv Y, Bai C, et al. Overexpression of spindlin1 induces metaphase arrest and chromosomal instability. J Cell Physiol. 2008;217(2):400-8.
37. Du Y, Yin F, Liu C, Hu S, Wang J, Xie H, et al. Depression of MAD2 inhibits apoptosis of gastric cancer cells by upregulating Bcl-2 and interfering mitochondrion pathway. Biochem Biophys Res Commun. 2006;345(3):1092-8.
38. Fujita T, Washio K, Takabatake D, Takahashi H, Yoshitomi S, Tsukuda K, et al. Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. Int J Cancer. 2005;117:670-82.
39. Zhao YQ, You H, Liu F, An HZ, Shi YQ, Yu Q, et al. Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. Cancer Lett. 2002;185:211-8.